|
|
by Claremont Creek Alerts on January 18th, 2012 
January 18, 2012 source: MedCity News
Personalized medicine company AssureRx Health has released the next-generation version of its genetic screening test for psychiatric drugs.
The Cincinnati-area company’s GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes, was launched in 2009. The test uses a cheek swab, mathematical algorithms and bioinformatics to narrow drug choices to those that work with a patient’s genes.
. . .
→ Read full post: Claremont Creek Ventures’ portfolio company AssureRX updates its psychiatric drugs screening test
by Claremont Creek Alerts on December 15th, 2011 
September 9, 2011 source: originally published in the San Francisco Business Times
Photo: Spencer Brown The winner “is the company that’s going to help families,” says GSN CEO Rabinowitz.
Gene Security Network’s race to develop safer, more accurate prenatal test is all business for Matt Rabinowitz — and it’s personal.
A relative of Rabinowitz, Gene Security Network’s CEO, took a blood test for the likelihood of Down’s syndrome in her unborn baby and . . .
→ Read full post: Claremont Creek Ventures’ portfolio company Gene Security Network in race for prenatal test
by Claremont Creek Alerts on October 10th, 2011 
October 9, 2011 source: CBS News
As part of CBS morning news, TIBION was profiled by correspondent Barry Peterson. At approximately four minutes 21 seconds into the video, see how TIBION stands out. We are proud of our portfolio company that is getting worldwide recognition.
The next step in bionics
…
The new world of high-tech prosthetics includes the Tibion Bionic limb, that helps stroke victims re-learn how to use . . .
→ Read full post: Claremont Creek Ventures portfolio company Tibion’s VP of Engineering Matt Murphy shows off the Tibion Bionic Limb on CBS Morning News
by John Steuart on September 12th, 2011 
Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If you are curious why this service might be helpful, see Dear Abby’s recent column below.
In . . .
→ Read full post: Why Dear Abby loves this company (and you should, too)
by Brad Webb on September 12th, 2011 
It is always great to brag and cheer about one of our portfolio companies. Working with portfolio companies to help them succeed is one of a VC’s key jobs, and helping build an executive team is an area where a VC can help a lot. We are pleased to announce that AssureRx Health has just added some super people to its team. The three executives are: Dr. C. Anthony Altar, PhD, chief science officer; . . .
→ Read full post: Claremont Creek Ventures portfolio company AssureRx Health expands senior management team
by John Steuart on July 22nd, 2011 
I will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center.
Here’s the panel topic summary, hope to see you there.
Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment. These . . .
→ Read full post: Molecular Diagnostics World Congress, Venture Capitalists’ Best Practices on Commercializing Innovation
by Brad Webb on July 6th, 2011 July 1, 2011 source: Genetic Engineering & Biotechnology News by Brad Webb
Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare
It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. As we point out in this article, cardiologists, psychiatrists, and internists can now order quick and inexpensive genetics-based screening . . .
→ Read full post: Moving Quickly from an Idea to a Product
John Steuart was a panelist at The Deal’s webcast audio seminar:
Technology Transfer in the 21st Century, on May 12, 2011
(also participating as a panelist – Jeff Jensen, CEO, Fluxion Biosciences Inc. a Claremont Creek Ventures portfolio company)
A recording of the seminar is now available to play online or download through 8/12/2011.
Click here to access the recording. The slides from the webcast are . . .
→ Read full post: Recording of “Technology Transfer in the 21st Century” webcast available
by Claremont Creek Alerts on April 6th, 2011 April 5, 2011 source: Gene Security Network press release
Gene Security Network (GSN) welcomes the birth of the first baby to be born following the use of GSN’s novel Parental SupportTM technology for single gene preimplantation genetic diagnosis (PGD) and concurrent 24-chromosome screening. This test allows couples who are at risk to have children with genetic disease to undergo embryo testing during an in vitro fertilization (IVF) cycle in order to . . .
→ Read full post: Claremont Creek Ventures portfolio company GSN’s testing technology helps couple achieve their dream of a healthy child
by Claremont Creek Alerts on March 7th, 2011 March 1, 2011 source: Enhanced Online News (EON)
- Three Arch Partners, Hambrecht & Quist lead financing, join board - Initial investor Claremont Creek Ventures also participates -
Tibion Corporation, the privately held Silicon Valley firm transforming stroke rehabilitation with its robotic Bionic Leg, announced today the successful closure of a $10.175 million financing round, a new board of directors, and a new board chairman.
“The new financing will enable us to . . .
→ Read full post: Claremont Creek Ventures portfolio company, Tibion Corporation announces new $10 Million financing round, new Board Chairman & Board Members
|
